Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,724,722 papers from all fields of science
Search
Sign In
Create Free Account
MIRN525 microRNA, human
Known as:
hsa-mir-525
, miR-525, human
, microRNA-525, human
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
MicroRNAs
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
EP18.09: Expression profile of C19MC microRNAs in placental tissue of patients with preterm prelabour rupture of membranes and spontaneous preterm birth
I. Hromadníková
,
K. Kotlabova
,
K. Ivankova
,
L. Krofta
2017
Corpus ID: 57633100
Objectives: To demonstrate that preterm birth is associated with altered C19MC microRNA expression profile in placental tissues…
Expand
2017
2017
EP18.10: First trimester screening maternal and biochemical factors affecting preterm delivery
M. Li
2017
Corpus ID: 79823475
Objectives: To demonstrate that preterm birth is associated with altered C19MC microRNA expression profile in placental tissues…
Expand
2015
2015
miR-525-5p inhibits ADAMTS13 and is correlated with Ischemia/reperfusion injury-induced neuronal cell death.
Liyan Zhao
,
C. Hua
,
Yunqian Li
,
Qingqing Sun
,
Wei Wu
International Journal of Clinical and…
2015
Corpus ID: 30043665
The understanding of molecular mechanism underlying ischemia/reperfusion-induced neuronal death and neurological dysfunction may…
Expand
2015
2015
miR-525-5 p inhibits ADAMTS 13 and is correlated with Ischemia / reperfusion injury-induced neuronal cell death
Liyan Zhao
,
C. Hua
,
Yunqian Li
,
Qingqing Sun
,
Wei Wu
2015
Corpus ID: 22355391
The understanding of molecular mechanism underlying ischemia/reperfusion-induced neuronal death and neurological dysfunction may…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE